Kali Therapeutics

News

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

News

In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.